Distinct Effects of T-705 (Favipiravir) and ribavirin on influenza virus replication and Viral RNA Synthesis

Antimicrobial Agents and Chemotherapy

Volumn 60, Issue 11, 2016, Pages 6679-6691

  Vanderlinden, Evelien ^a   Vrancken, Bram ^a   Houdt, Jeroen Van ^b   Rajwanshi, Vivek K ^c   Gillemot, Sarah ^a   Andrei, Graciela ^a   Lemey, Philippe ^a   Naesens, Lieve ^a  

^a REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^c Alios BioPharma Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FAVIPIRAVIR; INOSINATE DEHYDROGENASE; RIBAVIRIN; VIRUS RNA; AMIDE; ANTIVIRUS AGENT; DNA DIRECTED RNA POLYMERASE; PYRAZINE DERIVATIVE; VIRAL PROTEIN;

ANIMAL CELL; ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; ENZYME INHIBITION; HOST CELL; INFLUENZA; INFLUENZA VIRUS; NONHUMAN; PRIORITY JOURNAL; RNA SYNTHESIS; SEQUENCE ANALYSIS; VIRUS GENOME; VIRUS MUTATION; VIRUS REPLICATION; A-549 CELL LINE; ANIMAL; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; CHEMISTRY; CHICK EMBRYO; COMPARATIVE STUDY; DOG; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETIC REASSORTMENT; GENETICS; GROWTH, DEVELOPMENT AND AGING; HUMAN; INFLUENZA A VIRUS (H1N1); INFLUENZA A VIRUS (H3N2); MDCK CELL LINE; METABOLISM; MUTATION; STRUCTURE ACTIVITY RELATION;

A549 CELLS; AMIDES; ANIMALS; ANTIVIRAL AGENTS; CHICK EMBRYO; DNA-DIRECTED RNA POLYMERASES; DOGS; GENE EXPRESSION REGULATION, VIRAL; HUMANS; IMP DEHYDROGENASE; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA A VIRUS, H3N2 SUBTYPE; MADIN DARBY CANINE KIDNEY CELLS; MUTATION; PYRAZINES; REASSORTANT VIRUSES; RIBAVIRIN; RNA, VIRAL; SEQUENCE ANALYSIS, RNA; STRUCTURE-ACTIVITY RELATIONSHIP; VIRAL PROTEINS; VIRUS REPLICATION;

EID: 84994812705     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01156-16     Document Type: Article

References (56)

1. World Health Organization. March 2014. Influenza (seasonal). Fact sheet no. 211. World Health Organization, Geneva, Switzerland. http://www.who.int/mediacentre/factsheets/fs211/en/.
2. Glezen WP, Schmier JK, Kuehn CM, Ryan KJ, Oxford J. 2013. The burden of influenza B: A structured literature review. Am J Public Health 103:e43-e51. http://dx.doi.org/10.2105/AJPH.2012.301137.
3. Neumann G, Noda T, Kawaoka Y. 2009. Emergence and pandemic potential of swine-origin H1N1 influenza virus. Nature 459:931-939. http://dx.doi.org/10.1038/nature08157.
4. Biggerstaff M, Reed C, Swerdlow DL, Gambhir M, Graitcer S, Finelli L, Borse RH, Rasmussen SA, Meltzer MI, Bridges CB. 2015. Estimating the potential effects of a vaccine program against an emerging influenza pandemic-United States. Clin Infect Dis 60(Suppl 1):S20-S29. http://dx.doi.org/10.1093/cid/ciu1175.
5. Samson M, Pizzorno A, Abed Y, Boivin G. 2013. Influenza virus resistance to neuraminidase inhibitors. Antiviral Res 98:174-185. http://dx.doi.org/10.1016/j.antiviral.2013.03.014.
6. Jefferson T, Jones MA, Doshi P, Del Mar CB, Hama R, Thompson MJ, Spencer EA, Onakpoya I, Mahtani KR, Nunan D, Howick J, Heneghan CJ. 2014. Neuraminidase inhibitors for preventing and treating influenza in healthy adults and children. Cochrane Database Syst Rev 4:CD008965. http://dx.doi.org/10.1002/14651858.CD008965.
7. Muthuri SG, Venkatesan S, Myles PR, Leonardi-Bee J, Al Khuwaitir TS, Al MA, Anovadiya AP, Azziz-Baumgartner E, Baez C, Bassetti M, Beovic B, Bertisch B, Bonmarin I, Booy R, Borja-Aburto VH, Burgmann H, Cao B, Carratala J, Denholm JT, Dominguez SR, Duarte PA, Dubnov-Raz G, Echavarria M, Fanella S, Gao Z, Gerardin P, Giannella M, Gubbels S, Herberg J, Iglesias AL, Hoger PH, Hu X, Islam QT, Jimenez MF, Kandeel A, Keijzers G, Khalili H, Knight M, Kudo K, Kusznierz G, Kuzman I, Kwan AM, Amine IL, Langenegger E, Lankarani KB, Leo YS, Linko R, Liu P, Madanat F, Mayo-Montero E, McGeer A, Memish Z, Metan G, Mickiene A, Mikic D, Mohn KG, Moradi A, Nymadawa P, Oliva ME, Ozkan M, Parekh D, Paul M, Polack FP, Rath BA, Rodriguez AH, Sarrouf EB, Seale AC, Sertogullarindan B, Siqueira MM, Skret-Magierlo J, Stephan F, Talarek E, Tang JW, To KK, Torres A, Torun SH, Tran D, Uyeki TM, Van ZA, Vaudry W, Vidmar T, Yokota RT, Zarogoulidis P, Nguyen-Van-Tam JS. 2014. Effectiveness of neuraminidase inhibitors in reducing mortality in patients admitted to hospital with influenza A H1N1pdm09 virus infection: A meta-Analysis of individual participant data. Lancet Respir Med 2:395-404. http://dx.doi.org/10.1016/S2213-2600(14)70041-4.
8. Moscona A. 2008. Medical management of influenza infection. Annu Rev Med 59:397-413.
9. Stevaert A, Naesens L. 29 August 2016. The influenza virus polymerase complex: An update on its structure, functions and significance for antiviral drug design. Med Res Rev http://dx.doi.org/10.1002/med.21401.
10. Furuta Y, Takahashi K, Fukuda Y, Kuno M, Kamiyama T, Kozaki K, Nomura N, Egawa H, Minami S, Watanabe Y, Narita H, Shiraki K. 2002. In vitro and in vivo activities of anti-influenza virus compound T-705. Antimicrob Agents Chemother 46:977-981. http://dx.doi.org/10.1128/AAC.46.4.977-981.2002.
11. Sleeman K, Mishin VP, Deyde VM, Furuta Y, Klimov AI, Gubareva LV. 2010. In vitro antiviral activity of favipiravir (T-705) against drugresistant influenza and 2009 A(H1N1) viruses. Antimicrob Agents Chemother 54:2517-2524. http://dx.doi.org/10.1128/AAC.01739-09.
12. Sidwell RW, Barnard DL, Day CW, Smee DF, Bailey KW, Wong MH, Morrey JD, Furuta Y. 2007. Efficacy of orally administered T-705 on lethal avian influenza A (H5N1) virus infections in mice. Antimicrob Agents Chemother 51:845-851. http://dx.doi.org/10.1128/AAC.01051-06.
13. Furuta Y, Gowen BB, Takahashi K, Shiraki K, Smee DF, Barnard DL. 2013. Favipiravir (T-705), a novel viral RNA polymerase inhibitor. Antiviral Res 100:446-454. http://dx.doi.org/10.1016/j.antiviral.2013.09.015.
14. Furuta Y, Takahashi K, Shiraki K, Sakamoto K, Smee DF, Barnard DL, Gowen BB, Julander JG, Morrey JD. 2009. T-705 (favipiravir) and related compounds: novel broad-spectrum inhibitors of RNA viral infections. Antiviral Res 82:95-102. http://dx.doi.org/10.1016/j.antiviral.2009.02.198.
15. Toyama Chemical Co, Ltd. 24 March 2014. The new drug application approval of "AVIGAN® tablet 200mg" in Japan for the anti-influenza virus drug. Toyama Chemical Co, Ltd, Tokyo, Japan. https://www.toyama-chemical.co.jp/eng/news/news140324e.html.
16. Zumla A, Memish ZA, Maeurer M, Bates M, Mwaba P, Al-Tawfiq JA, Denning DW, Hayden FG, Hui DS. 2014. Emerging novel and antimicrobial-resistant respiratory tract infections: new drug development and therapeutic options. Lancet Infect Dis 14:1136-1149. http://dx.doi.org/10.1016/S1473-3099(14)70828-X.
17. McKimm-Breschkin JL, Fry AM. 2016. Meeting report: 4th ISIRV antiviral group conference: novel antiviral therapies for influenza and other respiratory viruses. Antiviral Res 129:21-38. http://dx.doi.org/10.1016/j.antiviral.2016.01.012.
18. Magnussen CR, Douglas RG, Jr, Betts RF, Roth FK, Meagher MP. 1977. Double-blind evaluation of oral ribavirin (Virazole) in experimental influenza A virus infection in volunteers. Antimicrob Agents Chemother 12:498-502. http://dx.doi.org/10.1128/AAC.12.4.498.
19. Stein DS, Creticos CM, Jackson GG, Bernstein JM, Hayden FG, Schiff GM, Bernstein DI. 1987. Oral ribavirin treatment of influenza A and B. Antimicrob Agents Chemother 31:1285-1287.
20. Centers for Disease Control and Prevention. 2009. Oseltamivir-resistant novel influenza A (H1N1) virus infection in two immunosuppressed patients-Seattle, Washington, 2009. MMWR Morb Mortal Wkly Rep 58: 893-896.
21. van der Vries E, Stelma FF, Boucher CA. 2010. Emergence of a multidrug-resistant pandemic influenza A (H1N1) virus. N Engl J Med 363: 1381-1382. http://dx.doi.org/10.1056/NEJMc1003749.
22. Kim WY, Young SG, Huh JW, Kim SH, Kim MJ, Kim YS, Kim HR, Ryu YJ, Han MS, Ko YG, Chon GR, Lee KH, Choi SH, Hong SB. 2011. Triple-combination antiviral drug for pandemic H1N1 influenza virus infection in critically ill patients on mechanical ventilation. Antimicrob Agents Chemother 55:5703-5709. http://dx.doi.org/10.1128/AAC.05529-11.
23. Furuta Y, Takahashi K, Kuno-Maekawa M, Sangawa H, Uehara S, Kozaki K, Nomura N, Egawa H, Shiraki K. 2005. Mechanism of action of T-705 against influenza virus. Antimicrob Agents Chemother 49:981-986. http://dx.doi.org/10.1128/AAC.49.3.981-986.2005.
24. Naesens L, Guddat LW, Keough DT, van Kuilenburg AB, Meijer J, Vande Voorde J, Balzarini J. 2013. Role of human hypoxanthine guanine phosphoribosyltransferase in activation of the antiviral agent T-705 (favipiravir). Mol Pharmacol 84:615-629. http://dx.doi.org/10.1124/mol.113.087247.
25. Baranovich T, Wong SS, Armstrong J, Marjuki H, Webby RJ, Webster RG, Govorkova EA. 2013. T-705 (favipiravir) induces lethal mutagenesis in influenza A H1N1 viruses in vitro. J Virol 87:3741-3751. http://dx.doi.org/10.1128/JVI.02346-12.
26. Cheung PP, Watson SJ, Choy KT, Fun SS, Wong DD, Poon LL, Kellam P, Guan Y, Malik Peiris JS, Yen HL. 2014. Generation and characterization of influenza A viruses with altered polymerase fidelity. Nat Commun 5:4794. http://dx.doi.org/10.1038/ncomms5794.
27. Pauly MD, Lauring AS. 2015. Effective lethal mutagenesis of influenza virus by three nucleoside analogs. J Virol 89:3584-3597. http://dx.doi.org/10.1128/JVI.03483-14.
28. Marathe BM, Wong SS, Vogel P, Garcia-Alcalde F, Webster RG, Webby RJ, Najera I, Govorkova EA. 2016. Combinations of oseltamivir and T-705 extend the treatment window for highly pathogenic influenza A(H5N1) virus infection in mice. Sci Rep 6:26742. http://dx.doi.org/10.1038/srep26742.
29. Jin Z, Smith LK, Rajwanshi VK, Kim B, Deval J. 2013. The ambiguous base-pairing and high substrate efficiency of T-705 (favipiravir) ribofuranosyl 5=-Triphosphate towards influenza A virus polymerase. PLoS One 8:e68347. http://dx.doi.org/10.1371/journal.pone.0068347.
30. Sangawa H, Komeno T, Nishikawa H, Yoshida A, Takahashi K, Nomura N, Furuta Y. 2013. Mechanism of action of T-705 ribosyl triphosphate against influenza virus RNA polymerase. Antimicrob Agents Chemother 57:5202-5208. http://dx.doi.org/10.1128/AAC.00649-13.
31. Eriksson B, Helgstrand E, Johansson NG, Larsson A, Misiorny A, Noren JO, Philipson L, Stenberg K, Stening G, Stridh S, Oberg B. 1977. Inhibition of influenza virus ribonucleic acid polymerase by ribavirin triphosphate. Antimicrob Agents Chemother 11:946-951. http://dx.doi.org/10.1128/AAC.11.6.946.
32. Wray SK, Gilbert BE, Knight V. 1985. Effect of ribavirin triphosphate on primer generation and elongation during influenza virus transcription in vitro. Antiviral Res 5:39-48. http://dx.doi.org/10.1016/0166-3542(85) 90013-0.
33. Wray SK, Gilbert BE, Noall MW, Knight V. 1985. Mode of action of ribavirin: effect of nucleotide pool alterations on influenza virus ribonucleoprotein synthesis. Antiviral Res 5:29-37.
34. Streeter DG, Witkowski JT, Khare GP, Sidwell RW, Bauer RJ, Robins RK, Simon LN. 1973. Mechanism of action of 1-b-D-ribofuranosyl-1, 2, 4-Triazole-3-carboxamide (Virazole), a new broad-spectrum antiviral agent. Proc Natl Acad Sci U S A 70:1174-1178. http://dx.doi.org/10.1073/pnas.70.4.1174.
35. Egawa H, Furuta Y, Murakami M, Takahashi K, Tsutsui Y, Uehara S. May 2004. Novel virus proliferation inhibition/virucidal method and novel pyradine nucleotide/pyradine nucleoside analogue. European patent EP 1417967 A1.
36. Vanderlinden E, Vanstreels E, Boons E, ter Veer W, Huckriede A, Daelemans D, Van LA, Roth E, Sztaricskai F, Herczegh P, Naesens L. 2012. Intracytoplasmic trapping of influenza virus by a lipophilic derivative of aglycoristocetin. J Virol 86:9416-9431. http://dx.doi.org/10.1128/JVI.07032-11.
37. Reed LJ, Muench H. 1938. A simple method of estimating fifty per cent endpoints. Am J Hyg 27:493-497.
38. Stevaert A, Dallocchio R, Dessi A, Pala N, Rogolino D, Sechi M, Naesens L. 2013. Mutational analysis of the binding pockets of the diketo acid inhibitor L-742, 001 in the influenza virus PA endonuclease. J Virol 87:10524-10538. http://dx.doi.org/10.1128/JVI.00832-13.
39. Vanderlinden E, Goktas F, Cesur Z, Froeyen M, Reed ML, Russell CJ, Cesur N, Naesens L. 2010. Novel inhibitors of influenza virus fusion: structure-Activity relationship and interaction with the viral hemagglutinin. J Virol 84:4277-4288. http://dx.doi.org/10.1128/JVI.02325-09.
40. Archer J, Baillie G, Watson SJ, Kellam P, Rambaut A, Robertson DL. 2012. Analysis of high-depth sequence data for studying viral diversity: A comparison of next generation sequencing platforms using Segminator II. BMC Bioinformatics 13:47. http://dx.doi.org/10.1186/1471-2105-13-47.
41. Balzarini J, Gago F, Kulik W, van Kuilenburg AB, Karlsson A, Peterson MA, Robins MJ. 2012. Introduction of a fluorine atom at C3 of 3-deazauridine shifts its antimetabolic activity from inhibition of CTP synthetase to inhibition of orotidylate decarboxylase, an early event in the de novo pyrimidine nucleotide biosynthesis pathway. J Biol Chem 287:30444-30454. http://dx.doi.org/10.1074/jbc.M112.378091.
42. Meneghesso S, Vanderlinden E, Brancale A, Balzarini J, Naesens L, McGuigan C. 2013. Synthesis and biological evaluation of purine 2=-fluoro-2=-deoxyriboside ProTides as anti-influenza virus agents. ChemMedChem 8:415-425. http://dx.doi.org/10.1002/cmdc.201200562.
43. Meneghesso S, Vanderlinden E, Stevaert A, McGuigan C, Balzarini J, Naesens L. 2012. Synthesis and biological evaluation of pyrimidine nucleoside monophosphate prodrugs targeted against influenza virus. Antiviral Res 94:35-43. http://dx.doi.org/10.1016/j.antiviral.2012.01.007.
44. Plotch SJ, Bouloy M, Ulmanen I, Krug RM. 1981. A unique cap(m7GpppXm)-dependent influenza virion endonuclease cleaves capped RNAs to generate the primers that initiate viral RNA transcription. Cell 23:847-858. http://dx.doi.org/10.1016/0092-8674(81)90449-9.
45. Rochovansky OM. 1976. RNA synthesis by ribonucleoprotein-polymerase complexes isolated from influenza virus. Virology 73:327-338. http://dx.doi.org/10.1016/0042-6822(76)90394-9.
46. Balzarini J, De Clercq E. 1992. Assay method for monitoring the inhibitory effects of antimetabolites on the activity of inosinate dehydrogenase in intact humanCEMlymphocytes. Biochem J 287:785-790. http://dx.doi.org/10.1042/bj2870785.
47. Smee DF, Hurst BL, Egawa H, Takahashi K, Kadota T, Furuta Y. 2009. Intracellular metabolism of favipiravir (T-705) in uninfected and influenza A (H5N1) virus-infected cells. J Antimicrob Chemother 64:741-746.
48. Paeshuyse J, Dallmeier K, Neyts J. 2011. Ribavirin for the treatment of chronic hepatitis C virus infection: A review of the proposed mechanisms of action. Curr Opin Virol 1:590-598. http://dx.doi.org/10.1016/j.coviro.2011.10.030.
49. Tisdale M, Ellis M, Klumpp K, Court S, Ford M. 1995. Inhibition of influenza virus transcription by 2=-deoxy-2=-fluoroguanosine. Antimicrob Agents Chemother 39:2454-2458. http://dx.doi.org/10.1128/AAC.39.11.2454.
50. Leyssen P, Balzarini J, De CE, Neyts J. 2005. The predominant mechanism by which ribavirin exerts its antiviral activity in vitro against flaviviruses and paramyxoviruses is mediated by inhibition of IMP dehydrogenase. J Virol 79:1943-1947. http://dx.doi.org/10.1128/JVI.79.3.1943-1947.2005.
51. Nayak DP. 1980. Defective interfering influenza viruses. Annu Rev Microbiol 34:619-644. http://dx.doi.org/10.1146/annurev.mi.34.100180.003155.
52. Graci JD, Cameron CE. 2008. Therapeutically targeting RNA viruses via lethal mutagenesis. Future Virol 3:553-566. http://dx.doi.org/10.2217/17460794.3.6.553.
53. Raab M, Daxecker H, Karimi A, Markovic S, Cichna M, Markl P, Muller MM. 2001. In vitro effects of mycophenolic acid on the nucleotide pool and on the expression of adhesion molecules of human umbilical vein endothelial cells. Clin Chim Acta 310:89-98. http://dx.doi.org/10.1016/S0009-8981(01)00527-7.
54. Dimmock NJ, Easton AJ. 2014. Defective interfering influenza virus RNAs: Time to reevaluate their clinical potential as broad-spectrum antivirals? J Virol 88:5217-5227. http://dx.doi.org/10.1128/JVI.03193-13.
55. Brooke CB. 2014. Biological activities of 'noninfectious' influenza A virus particles. Future Virol 9:41-51. http://dx.doi.org/10.2217/fvl.13.118.
56. Quiles-Pérez R, Munoz-de-Rueda P, Maldonado AM, Martin-Alvarez A, Quer J, Salmeron J. 2014. Effects of ribavirin monotherapy on the viral population in patients with chronic hepatitis C genotype 1: direct sequencing and pyrosequencing of the HCV regions. J Med Virol 86:1886-1897. http://dx.doi.org/10.1002/jmv.24035.